Assessment of the genotoxicity of the tyrosine kinase inhibitor imatinib mesylate in cultured fish and human cells

详细信息    查看全文

• 作者：Matjaž Novak^a ; ^b ; ^c ; ^{matjaz.novak@nib.si} ; Bojana Žegura^a ; ^{bojana.zegura@nib.si} ; Jana Nunić^a ; ^{jana1rs@yahoo.com} ; Goran Gajski^d ; ^{ggajski@imi.hr} ; Marko Gerić^d ; ^{mgeric@imi.hr} ; Vera Garaj-Vrhovac^d ; ^{vgaraj@imi.hr} ; Metka Filipič^a ; ^{metka.filipic@nib.si}
• 关键词：Imatinib mesylate ; Cytotoxic ; Genotoxic ; Zebrafish liver cells ; HepG2 cells ; Human peripheral blood lymphocytes
• 刊名：Mutation Research/Genetic Toxicology and Environmental Mutagenesis
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：814
• 期：Complete
• 页码：14-21
• 全文大小：1568 K
• 卷排序：814

文摘

Imatinib mesylate was developed for targeted cancer chemotherapy. At present it is one of the most wildly used anticancer drugs in developed countries. It is not mutagenic in bacterial reverse mutation assays (Ames test). In vitro it induces DNA damage and micronuclei in human and fish derived non-target cells. Genotoxic effects occur at concentrations higher than PEC values.